What a drugmaker can learn from patientsEisai's neurology pipeline built over four decades with dedication to patient-centric research & development.
Lilly wins FDA approval for new drug to slow Alzheimer'sThe FDA cleared Eli Lilly's Alzheimer's treatment, offering competition to Eisai's drug at a slightly higher cost, emphasizing the potential cost advantage and convenience of Lilly's treatment.